|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5120 SEK | -1.92% |
|
-7.58% | +96.92% |
| 08-21 | Annexin Reports Promising Topline Results in RVO Phase 2A Study | CI |
| 07-18 | Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
| Capitalization | 273M 26.5M 2.02B | P/E ratio 2024 * |
-
| P/E ratio 2025 * | - |
|---|---|---|---|---|---|
| Enterprise value | 264M 25.63M 1.95B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | 5.3x |
| Free-Float |
22.68% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | -1.92% | ||
| 1 week | -7.58% | ||
| Current month | -7.58% | ||
| 1 month | -35.19% | ||
| 3 months | +7.79% | ||
| 6 months | +116.03% | ||
| Current year | +96.92% |
1 week
0.49
0.60
1 month
0.490.83
Current year
0.200.93
1 year
0.200.98
3 years
0.202.25
5 years
0.203.30
10 years
0.2013.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/17 | |
Anna Frostegård
FOU | Founder | 51 | 31/12/13 |
| Director of Finance/CFO | 53 | 10/04/23 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 31/12/16 | |
| Director/Board Member | 71 | - | |
Jan Nilsson
CHM | Chairman | 75 | 12-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.92% | -7.58% | -24.71% | -74.01% | 26.58M | ||
| -1.66% | -4.49% | +37.11% | +69.18% | 122B | ||
| -0.12% | -5.62% | +36.06% | +143.50% | 121B | ||
| +0.27% | +4.17% | +1.75% | +67.91% | 32.37B | ||
| -0.23% | +1.95% | -24.88% | -74.05% | 21.38B | ||
| -0.14% | -0.24% | -1.51% | -44.80% | 20.33B | ||
| -0.27% | -0.72% | -29.20% | -37.25% | 17.58B | ||
| -2.17% | -0.97% | -49.15% | -72.52% | 15.54B | ||
| -0.46% | +38.16% | +123.97% | +330.81% | 12.45B | ||
| -3.63% | -5.05% | +5.67% | +64.08% | 12.29B | ||
| Average | -1.03% | +2.34% | +7.51% | +37.28% | 37.49B | |
| Weighted average by Cap. | -0.81% | -1.63% | +23.25% | +76.32% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | - | 51.5M 5M 381M |
| Net income | -61.5M -5.97M -455M | -14M -1.36M -104M |
| Net Debt | -9M -874K -66.56M | - |
More financial data
* Estimated data
Employees
4
Calendar
30/10/2024
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/09/24 | 0.5120 kr | -1.92% | 270,147 |
| 05/09/24 | 0.5220 kr | -1.51% | 168,267 |
| 04/09/24 | 0.5300 kr | +3.11% | 136,600 |
| 03/09/24 | 0.5140 kr | -4.81% | 319,536 |
| 02/09/24 | 0.5400 kr | -2.53% | 374,481 |
Delayed Quote Nasdaq Stockholm, September 06, 2024 at 05:00 pm
More quotesChiffre d''affaires - Rate of surprise
- Stock Market
- Equities
- ANNX Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition